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Abstract
Purpose To determine the influence of two commonly occurring genetic polymorphisms on exercise, cognitive performance, 
and caffeine metabolism, after caffeine ingestion.
Methods Eighteen adults received caffeine or placebo (3 mg kg−1) in a randomised crossover study, with measures of endur-
ance exercise (15-min cycling time trial; 70-min post-supplementation) and cognitive performance (psychomotor vigilance 
test; PVT; pre, 50 and 95-min post-supplementation). Serum caffeine and paraxanthine were measured (pre, 30 and 120-min 
post-supplementation), and polymorphisms in ADORA2A (rs5751876) and CYP1A2 (rs762551) genes analysed.
Results Caffeine enhanced exercise performance (P < 0.001), but effects were not different between participants with 
ADORA2A ‘high’ (n = 11) vs. ‘low’ (n = 7) sensitivity genotype (+ 6.4 ± 5.8 vs. + 8.2 ± 6.8%), or CYP1A2 ‘fast’ (n = 10) vs. 
‘slow’ (n = 8) metabolism genotype (+ 7.2 ± 5.9 vs. + 7.0 ± 6.7%, P > 0.05). Caffeine enhanced PVT performance (P < 0.01). 
The effect of caffeine was greater for CYP1A2 ‘fast’ vs. ‘slow’ metabolisers for reaction time during exercise (− 18 ± 9 vs. 
− 1.0 ± 11 ms); fastest 10% reaction time at rest (− 18 ± 11 vs. − 3 ± 15 ms) and lapses at rest (− 3.8 ± 2.7 vs. + 0.4 ± 0.9) 
(P < 0.05). There were no PVT differences between ADORA2A genotypes (P > 0.05). Serum caffeine and paraxanthine 
responses were not different between genotypes (P > 0.05).
Conclusion Caffeine enhanced CYP1A2 ‘fast’ metabolisers’ cognitive performance more than ‘slow’ metabolisers. No 
other between-genotype differences emerged for the effect of caffeine on exercise or cognitive performance, or metabolism.
Keywords Endurance exercise · Cognitive performance · Caffeine · Ergogenic · Genetics · Polymorphism
Abbreviations
ANOVA  Analysis of variance
BMI  Body mass index
BSA  Bovine serum albumin
DNA  Deoxyribonucleic acid
HPLC  High-performance liquid chromatography
L  Linear factor
PVT  Psychomotor vigilance test
RPE  Rating of perceived exertion
rpm  Revolutions per minute
SD  Standard deviation




  Maximal oxygen uptake
Wmax  Maximal test workload
Introduction
Caffeine is used globally by shift workers, military person-
nel, athletes, and others who need to overcome fatigue or 
prolong their capacity to complete occupational activities 
(Burke 2008). The ergogenic properties of caffeine were 
first reported more than a century ago (Rivers and Webber 
1907), with its effects in reducing fatigue and enhancing 
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wakefulness now well described (McLellan et al. 2016). 
Despite generally beneficial effects of caffeine on exercise 
and cognitive performance, sizeable inter-individual varia-
tions have been reported, including an absence of a positive 
effect in some individuals (Ganio et al. 2009; Grgic et al. 
2018, 2019; Jenkins et al. 2008; McLellan et al. 2016; South-
ward et al. 2018). The efficacy of caffeine supplementation is 
affected by the dose, method and timing of ingestion, train-
ing status, and the performance measures examined (Burke 
2008; McLellan et al. 2016). Evidence suggests genetic 
polymorphisms also influence an individual’s response to 
caffeine (Cornelis et al. 2006; Palatini et al. 2009; Retey 
et al. 2007). Mechanistically, caffeine is a potent adenosine 
receptor antagonist—caffeine blocks the actions of adeno-
sine in the central nervous system, thereby decreasing feel-
ings of tiredness and enhancing arousal, vigilance, and will-
ingness to exert effort during exercise (Meeusen et al. 2013). 
The rs5751876 single-nucleotide polymorphism (SNP) in 
the ADORA2A gene which encodes for the adenosine A2A 
receptor has been used to categorise individuals as having 
a ‘high’ (TT genotype) or ‘low’ (CT or CC genotype) sen-
sitivity to caffeine, and may account, in part, for some of 
this variability (Nehlig 2018). The P450 enzyme is respon-
sible for 95% of the body’s caffeine metabolism—convert-
ing caffeine to its major metabolite paraxanthine—hence a 
polymorphism in the gene which encodes for the CYP1A2 
isoform may also be responsible for some inter-individual 
differences. The rs762551 SNP can affect CYP1A2 enzyme 
activity and has been used to identify individuals as ‘fast’ 
(AA genotype) or ‘slow’ (AC or CC genotype) caffeine 
metabolisers (Nehlig 2018).
Only one study has examined the impact of ADORA2A 
genotype on the efficacy of caffeine in enhancing exercise 
performance, and it studied women only (Loy et al. 2015). 
Caffeine was found to improve 10-min time trial cycling 
performance in all participants with ‘high’ sensitivity, but 
in only one participant with ‘low’ sensitivity to caffeine. 
The largest randomised-controlled trial to examine CYP1A2 
genotype and exercise performance found caffeine enhanced 
10-km time trial cycling performance among only ‘fast’ 
caffeine metabolisers (Guest et al. 2018). Similarly, ‘fast’ 
metabolisers demonstrated a greater improvement in 40-km 
time trial performance following caffeine ingestion than 
‘slow’ metabolisers (Womack et al. 2012). In contrast, caf-
feine increased power output to a greater extent in ‘slow’ 
compared with ‘fast’ metabolisers in a later study by the 
same laboratory (Pataky et al. 2016); but no effect of geno-
type was observed in their more recent study (Giersch et al. 
2018), with both of these studies using a 3-km time trial to 
assess performance. As such, evidence to support an influ-
ence of CYP1A2 genotype on exercise performance is equiv-
ocal. Sleep-deprived individuals with ADORA2A ‘high’ 
sensitivity were found to have faster response times in a test 
of sustained attention after caffeine consumption than those 
with ‘low’ sensitivity (Bodenmann et al. 2012). Whether dif-
ferences persist without sleep deprivation remains unclear. 
For example, caffeine was ergogenic for individuals with 
‘high’ but not ‘low’ sensitivity to caffeine for one measure 
of reaction time, and vice versa for another (Renda et al. 
2015). In the only study to date, CYP1A2 genotype did not 
influence visual attention test performance; however, the 
authors unexpectedly found that caffeine was not ergogenic 
for cognitive performance (Salinero et al. 2017). Interpret-
ing the existing literature is further complicated by the fact 
that all but one of the aforementioned studies did not ana-
lyse the effect of genotype on caffeine metabolism (Giersch 
et al. 2018), to determine if/how this relates to any ergogenic 
differences.
The influence of genetic differences on the ergogenic 
effects of caffeine remains to be fully elucidated. To date, no 
single study has investigated the effect of both ADORA2A 
and CYP1A2 SNPs on exercise, cognitive performance or 
caffeine metabolism. Examining the influence of two com-
monly occurring genetic polymorphisms will give greater 
insight into potential mechanisms responsible for inter-indi-
vidual variability. It has been suggested that these SNPs can 
provide further understanding of how an individual is likely 
to respond to caffeine and has the potential to underpin a 
move from a one-size-fits-all, to a personalised approach to 
the use of this popular ergogenic aid (Pickering and Kiely 
2018). Therefore, the objective of this study was to deter-
mine the influence of ADORA2A and CYP1A2 SNPs on 
exercise, cognitive performance, and caffeine metabolism, 
after caffeine ingestion. It was hypothesised that the benefi-
cial effects of caffeine would be greatest in individuals with 
‘high’ sensitivity to caffeine (ADORA2A, TT genotype) and 
‘fast’ caffeine metabolism (CYP1A2, AA genotype).
Methods
Participants
Eighteen young, healthy, active adults voluntarily gave 
written informed consent to participate in the study after 
being fully informed of the study procedures, verbally 
and in writing (age 24 ± 4 years; n = 12 men: body mass 
74.7 ± 7.0  kg; height 1.78 ± 0.08  m; maximal oxygen 
uptake ( V̇O
2max
 ) 49.5 ± 7.7 mL kg−1 min−1; n = 6 women: 
body mass 62.7 ± 10.4 kg; height 1.69 ± 0.08 m; V̇O
2max
 
43.2 ± 10.6 mL kg−1 min−1). All participants were free 
from any known immune, cardiovascular or metabolic dis-
eases; were free from injury or illness; and were not tak-
ing any medication. Participants’ habitual daily caffeine 
intake was estimated using a food-frequency questionnaire 
and the typical caffeine content of consumed food, drink, 
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and supplements (Burke 2008; Fitt et al. 2013; McLellan 
et al. 2016). Using previously defined thresholds (Womack 
et al. 2012), 13 participants were categorised as having a 
low caffeine intake (0–150 mg day−1); two participants had 
a moderate intake (151–300 mg day−1); and 3 participants 
had a high intake (> 300 mg day−1). The study received ethi-
cal approval from the University of Kent, School of Sport 
and Exercise Sciences Research Ethics and Advisory Group, 
and was conducted in accordance with the Declaration of 
Helsinki (2013).
Study design
Using a double-blind, placebo-controlled crossover design, 
the effects of caffeine on endurance exercise performance, 
cognitive performance, and serum caffeine and paraxan-
thine were investigated. Caffeine and placebo trials were 
undertaken by participants in a randomised order, separated 
by 3–9 days, and a minimum of 2 days after completing 
preliminary measures. Using genomic DNA extracted from 
whole blood samples, SNPs in ADORA2A (rs5751876) and 
CYP1A2 (rs762551) genes were analysed, and the ergogenic 
effects of caffeine were compared between participants, cat-
egorised according to their genotype.
Preliminary measures and familiarisation
Anthropometric measures were recorded on arrival at the 
laboratory. Following this, V̇O
2max
 was measured during 
a step incremental exercise test on an electromagnetically 
braked cycle ergometer (Excalibor Sport, Lode, Groningen, 
The Netherlands). The step incremental exercise test began 
at a power output of 100 W, increasing by 25 W every 3 min 
up to 200 W, following which the power output increased 
by 25 W every minute until participants reached volitional 
exhaustion. Pulmonary gas exchange was measured breath-
by-breath for the duration of the test (Metalyser 3B, Cortex 
Biophysik, Leipzig, Germany). From this, the power output 
which elicited 70% V̇O
2max
 was calculated by interpolation 
of the power output–V̇O
2max
 relationship (using data from 
the submaximal stages). Maximal test workload (Wmax) was 
determined using the formula: Wmax = power of the last fully 
completed stage + (t/60)·25 W where t was the duration (in 
seconds) of the final stage (Jeukendrup et al. 1997). For 
example, if a participant reached volitional exhaustion after 
24 s of the 325 W stage, their Wmax = 310 W. After 30-min 
rest, participants performed a familiarisation trial to verify 
the power output prescription of 70% V̇O
2max
 and accustom 
themselves to all trial procedures and tasks. Participants 
cycled for 20 min at the power output estimated to elicit 
70% V̇O
2max
 . After 5-min rest, participants then completed a 
15-min cycling time trial during which they were instructed 
to perform as much work as possible. The ergometer was set 
in the linear mode, whereby the work rate increased linearly 
as a function of pedalling rate (squared). Linear mode was 
set according to the formula: L = 0.8·Wmax/(rpm)2 where L 
was the linear factor, Wmax the maximal workload (from the 
step incremental test), and rpm the pedalling rate. Eighty 
percent of Wmax was chosen following pilot testing, whereby 
the relative workload used by Jeukendrup et al. (1997) was 
increased to account for the shorter duration time trial used 
in the present study. The pedalling rate was determined from 
each participant’s average cadence during the step incre-
mental exercise test. Participants were familiarised to the 
10-min psychomotor vigilance test (PVT) by completing 
the test three times: twice whilst at rest and once during the 
20 min of cycling at 70% V̇O
2max
 . Three familiarisations 
were deemed sufficient to mitigate against learning effects 
(Lim and Dinges 2008).
Experimental trials
Participants reported to the laboratory after an overnight 
fast, and having avoided the consumption of caffeine-con-
taining drinks, foods, and supplements for 48 h to control 
for any effect their habitual caffeine intake might have on the 
ergogenic effects of caffeine; and strenuous exercise for 24 h. 
Both caffeine and placebo trials were completed at the same 
time of day. Participants were given diet diaries to record all 
food and beverages consumed during the 24 h before their 
first experimental trial and instructed to replicate this before 
their second trial. On arrival at the laboratory, participants 
completed a pre-supplementation PVT whilst at rest and 
then provided a venous blood sample (Fig. 1). Participants 
then consumed a capsule containing 3-mg kg−1 body mass 
of caffeine (Food Grade; Sigma-Aldrich, Missouri, USA) 
during the caffeine trial, and an identical-looking capsule 
containing 3-mg kg−1 body mass of microcrystalline cel-
lulose during the placebo trial. The capsule was swallowed 
with water proportional to their body mass (3-mL kg−1 
body mass). During a subsequent 30 min of seated rest, 
participants consumed water ab libitum in their first trial 
and an equal volume in their second trial. Participants then 
provided a second blood sample. Forty-five minutes after 
consuming the caffeine or placebo capsule, participants 
commenced 20 min of cycling at the power output to elicit 
70% V̇O
2max
 . Participants completed a PVT during minutes 
6–15, whilst continuing to exercise. After 5-min rest, dur-
ing which participants consumed water (2 mL kg−1 body 
mass), participants completed a 15-min cycling time trial. 
Following 10-min rest, participants completed a PVT whilst 
at rest, and provided a final venous blood sample, ~ 120-min 
post-supplementation (118.5 ± 4.9 min). Participants wore a 
heart rate monitor during cycling, with heart rate recorded 
every minute (Polar Electro, Kempele, Finland). For the first 
11 participants, rating of perceived exertion (RPE) was not 
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recorded to minimise any interference and interaction with 
participants that might affect the primary study outcomes. 
After completing these trials, it was apparent that recording 
RPE using the Borg Scale during cycling at 70% V̇O
2max
 
would be acceptable (during the 5-min periods before and 
after the PVT), so this measure was included for the final 
seven participants. All PVTs and cycling were completed in 
an environmental chamber (temperature 18.4 ± 1.0 °C; rela-
tive humidity 49.0 ± 7.5%).
Endurance exercise performance
Participants were instructed to perform as much work as pos-
sible during the 15-min cycling time trial. All participants 
were briefed using the same standardised instructions before 
commencing cycling. The environmental chamber was silent 
and the only information which the participant received was 
the time remaining displayed on a digital timer in front of 
them. No fluids were consumed during the 15-min time trial. 
The ergometer was connected to a computer which calcu-
lated the total work performed, and was reported relative to 
their body mass.
Cognitive performance
The 10-min PVT was completed on a laptop computer as a 
test of participants’ sustained attention (E-Prime, Psychol-
ogy Software Tools, Sharpsburg, Pennsylvania, USA; Lim 
and Dinges 2008). Participants were instructed to focus on 
the screen for the whole test duration and press a response 
button as soon as a target appeared in the centre of the com-
puter screen, which stopped the counter and displayed the 
reaction time for a 1-s period. The inter-stimulus interval, 
defined as the period between the last response and the 
appearance of the next stimulus, varied randomly from 2 
to 10 s. Participants were instructed to press the button as 
soon as each stimulus appeared, to keep the reaction time as 
low as possible but not press the button too soon. Responses 
without a stimulus or with a reaction time < 100 ms were 
not counted. The primary PVT outcome measure was the 
mean reaction time. In addition, the following outcome met-
rics were analysed: mean fastest 10% reaction time; 1/reac-
tion time (known as response speed); slowest 10% response 
speed; and number of lapses. Lapses were defined as a reac-
tion time > 500 ms and were excluded from reaction time 
and response speed analyses (Lim and Dinges 2008). The 
PVT was conducted at rest whilst seated at a table, and dur-
ing exercise on a cycle ergometer. During exercise, the key-
board was attached to the handlebars of the cycle ergometer. 
Participants wore their own spectacles during all PVTs as 
required. The environmental chamber was silent during all 
PVTs to minimise any distractions.
Blood collection and handling
Whole blood samples were collected by venepuncture from 
an antecubital vein into one plain vacutainer tube and one 
 K2EDTA tube (Becton Dickinson, Oxford, UK). An aliquot 
of whole blood was taken from the  K2EDTA tube and refrig-
erated at 4 °C for up to 48 h before the extraction of DNA. 
Whole blood in plain vacutainer tubes was left to clot for 
1 h. Subsequently, samples were centrifuged at 1500g for 
10 min at 4 °C and serum aliquots stored at − 80 °C for later 
analysis.
Serum caffeine and paraxanthine
Serum caffeine and paraxanthine concentrations were meas-
ured by high-performance liquid chromatography (HPLC) 
using a method modified from Holland et al. (1998). In 
Fig. 1  Schematic of experimental procedures. PVT psychomotor vigilance test; Syringe icon represents venous blood sample collected pre-sup-
plementation, and 30 min and ~ 120 min post-supplementation
European Journal of Applied Physiology 
1 3
preparation for analysis, serum samples were deproteinised 
by mixing 250 μL of thawed serum with 250 μL of 0.8-
mol L−1 perchloric acid. Proteins were removed by centri-
fuging at 14,000g for 4 min at 18 °C. A 350-μL sample 
of supernatant was aliquoted into a 1.5-mL polypropylene 
microcentrifuge tube, and mixed with 27 μL of 4-mol L−1 
sodium hydroxide, before being frozen at − 80 °C for later 
analysis. Deproteinised samples were defrosted and ali-
quoted into glass HPLC vials ready for analysis on an Agi-
lent 1100 LC system fitted with a vacuum degasser, col-
umn oven, and diode array detector (Agilent Technologies, 
Santa Clara, California, USA). Caffeine and its metabolites 
were separated on a Phenomenex Synergi Hydro-RP col-
umn, 50 × 2.0 mm (2.5-μm particle size; Phenomenex, Mac-
clesfield, UK). Deproteinised sample (5 μL) was injected, 
by autoinjector, and eluted isocratically over 10 min with 
15  mmol  L−1 potassium phosphate (pH 5.8):methanol 
(85:15, v/v) at a flow rate of 0.2 mL min−1 and column 
temperature of 30 °C. The column was flushed for 5 min 
with acetonitrile:water (80:20, v/v) and then re-equilibrated 
with the elution buffer for 10 min also at a flow rate of 
0.2 mL min−1 and column temperature of 30 °C. Caffeine 
and its metabolites were detected by UV absorbance at 
274 nm and peaks integrated with Agilent’s Chemstation 
software. Primary aqueous standards of caffeine and parax-
anthine were prepared by dilution of a weighed sample of 
each substance (Sigma-Aldrich) into a defined volume of 
deionised water to give a concentration of 1 mg mL−1. An 
intermediate standard containing 100 μg mL−1 of both caf-
feine and paraxanthine was prepared by dilution of the pri-
mary standards in 5% bovine serum albumin (BSA; Sigma-
Aldrich). The working standards for assay calibration (5, 
2.5, 0.625, 0.156, 0.078, and 0.039 μg mL−1) were prepared 
by serial dilution of the intermediate standards in 5% BSA. 
Unspiked 5% BSA was used as a blank, and 0.625 μg mL−1 
of caffeine and paraxanthine in 5% BSA used as a quality 
control, run after every 10 samples. A first tranche of analy-
sis was completed for the first 11 participants. Data from 
our pilot study in 16 men and women also found no effect 
of genotype on caffeine metabolism 30- and 120-min post-
caffeine ingestion (3 mg kg−1 body mass; Online Resource 
Supplementary Fig. 1); hence, it was deemed unnecessary 
to analyse serum caffeine and paraxanthine in the final seven 
participants.
ADORA2A and CYP1A2 genotype
Genomic DNA was isolated from whole blood using the 
Zymo Miniprep Kit (Quick-DNA Miniprep Plus Kit, Zymo 
Research, Irvine, California, USA) and immediately frozen 
at − 80 °C for later analysis. Genotyping of the rs5751876 
and rs762551 SNPs in the ADORA2A and CYP1A2 
genes, respectively, was completed using rhAmp assays 
(Integrated DNA Technologies, Coralville, Iowa, USA). 
For the ADORA2A gene, participants were categorised as 
either TT homozygotes (‘high’ sensitivity) or carriers of 
the C allele (i.e., CT heterozygotes and CC homozygotes; 
‘low’ sensitivity). For the CYP1A2 gene, participants were 
categorised as either AA homozygotes (‘fast’ metabolis-
ers) or carriers of the C allele (i.e., AC heterozygotes and 
CC homozygotes; ‘slow’ metabolisers). Genotyping was 
conducted after participants had completed their experi-
mental trials.
Statistical analysis
A sample size estimation was calculated using the effect 
size reported by Loy and colleagues’ pilot study which 
used a 10-min time trial to assess exercise performance 
(Loy et al. 2015): Cohen’s d = − 1.89 for the difference 
in the beneficial effect of caffeine between ADORA2A 
genotypes (‘high’ vs. ‘low’ sensitivity). With alpha level 
set at 0.05, and power set at 0.8, recruiting 12 participants 
was deemed appropriate to detect a statistically signifi-
cant difference in endurance exercise performance between 
ADORA2A genotypes (G*Power, version 3.1.9.2). One 
participant’s PVT data were excluded from analyses, 
because their number of lapses during exercise was > 2.5 
standard deviations from the mean (Lee et al. 2010). Their 
profile also suggested that they did not follow the PVT 
instructions (i.e., focus on the screen for the duration of 
the test) during exercise. All data were checked for nor-
mality and sphericity. Independent t tests were used to 
analyse between-genotype differences in participant char-
acteristics. Paired t tests were used to analyse the effect 
of caffeine on endurance exercise performance, heart rate, 
and RPE. Two-way repeated-measures ANOVA was used 
to analyse PVT reaction time, and serum caffeine, parax-
anthine, and the paraxanthine:caffeine ratio, with Green-
house–Geisser correction applied to the degrees of free-
dom if necessary. Bonferroni-adjusted paired t test post 
hoc procedures were used to determine within-participant 
differences where appropriate. Paraxanthine:caffeine ratio 
was not normally distributed; thus, a square root transfor-
mation was used to correct its positive skew. Caffeine–pla-
cebo change scores were calculated for endurance exercise 
performance, heart rate, PVT metrics, and serum caffeine 
and paraxanthine; with independent t tests used to ana-
lyse between-genotype differences. Where differences 
emerged, Cohen’s d effect sizes were calculated for the 
difference between change scores, where Cohen’s d greater 
than 0.2, 0.5, and 0.8 represent small, medium, and large 
effects, respectively (Cohen 1988). Data are presented 
as mean ± SD. Statistical analyses were performed using 
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SPSS Statistics 25.0 (IBM, Armonk, New York, USA). 
Statistical significance was accepted at P < 0.05.
Results
ADORA2A and CYP1A2 genotype
For the rs5751876 SNP in the ADORA2A gene, 11 par-
ticipants were homozygous for the T allele (TT, i.e., ‘high’ 
sensitivity); 6 participants were homozygous for the C allele 
(CC, i.e., ‘low’ sensitivity); and 1 participant was heterozy-
gous (CT, i.e., ‘low’ sensitivity). For the rs762551 SNP in 
the CYP1A2 gene, 10 participants were homozygous for 
the A allele (AA, i.e., ‘fast’ metabolisers); 7 participants 
were heterozygous carriers of the C allele (AC, i.e., ‘slow’ 
metabolisers); and 1 participant was homozygous for the 
C allele (CC, i.e., ‘slow’ metaboliser). Seven participants 
were categorised as ‘high’ sensitivity, ‘fast’ metabolisers 
(i.e., ADORA2A, AA, and CYP1A2, TT). Participant char-
acteristics were not different between genotypes (P > 0.05, 
Table 1); except ‘low’ sensitivity participants were taller 
than ‘high’ sensitivity participants (P < 0.05).
Endurance exercise performance
Caffeine increased the total work completed during the 
15-min cycling time trial by + 7.1 ± 6.1% compared with 
placebo (P < 0.001). The effect of caffeine on the total 
work completed was not different between ADORA2A 
genotypes (‘high’ sensitivity + 6.4 ± 5.8% vs. ‘low’ 
sensitivity + 8.2 ± 6.8%; P > 0.05, Fig. 2a, b). Similarly, 
the effect of caffeine on the total work completed was 
not different between CYP1A2 genotypes (‘fast’ metabo-
lisers + 7.2 ± 5.9% vs. ‘slow’ metabolisers + 7.0 ± 6.7%; 
P > 0.05, Fig. 2c, d). Finally, the effect of caffeine on the 
total work completed was not different between ‘high’ 
sensitivity, ‘fast’ metabolisers compared with all oth-
ers (‘high’ sensitivity, ‘fast’ metabolisers + 5.4 ± 3.4% vs. 
‘others’ + 8.2 ± 7.2%; P > 0.05). Caffeine increased mean 
heart rate during the time trial compared with placebo (caf-
feine 179 ± 11 bpm vs. placebo 174 ± 12 bpm, P < 0.01), 
but not during 20 min of cycling at 70% V̇O
2max
 (caffeine 
158 ± 13 bpm vs. placebo 158 ± 11 bpm, P > 0.05). The 
effect of caffeine on mean heart rate during the time trial was 
not different between ADORA2A genotypes (‘high’ sensitiv-
ity + 5 ± 5 bpm vs. ‘low’ sensitivity + 4 ± 5 bpm; P > 0.05); 
CYP1A2 genotypes (‘fast’ metabolisers + 5 ± 5 bpm vs. 
‘slow’ metabolisers + 4 ± 6  bpm; P > 0.05); or between 
‘high’ sensitivity, ‘fast’ metabolisers compared with all 
others (‘high’ sensitivity, ‘fast’ metabolisers + 5 ± 4 bpm 
vs. ‘others’ + 4 ± 6 bpm; P > 0.05). In the seven participants 
for whom RPE was measured during 20 min of cycling at 
70% V̇O
2max
 , there were no differences between caffeine 
and placebo at any time (minute 1: 11.6 ± 0.8 vs. 11.5 ± 1.0; 
minute 5: 13.3 ± 1.1 vs. 13.4 ± 0.9; minute 17: 14.4 ± 1.0 vs. 
15.2 ± 1.5; minute 20: 14.9 ± 1.4 vs. 15.1 ± 1.6, all P > 0.05). 
No differences in RPE were apparent between genotypes.
Cognitive performance
Caffeine improved cognitive performance, with 
faster mean reaction times during exercise and at rest 
Table 1  Participant 
characteristics
Participants are categorised according to ADORA2A (‘high’ or ‘low’ sensitivity) and CYP1A2 genotypes 
(‘fast’ or ‘slow’ metaboliser)
BMI body mass index, V̇O
2max
 maximal oxygen uptake, Wmax maximal test workload. Low, moderate, and 
high caffeine intake: 0–150, 151–300, and > 300 mg day−1, respectively. Data are mean ± SD, and n for sex 
and caffeine intake categories
# P < 0.05, ‘high’ vs. ‘low’ sensitivity
ADORA2A CYP1A2
‘High’ ‘Low’ ‘Fast’ ‘Slow’
Male 7 5 7 5
Female 4 2 3 3
Age (years) 23 ± 4 24 ± 5 23 ± 3 25 ± 5
Body mass (kg) 67.8 ± 10.5 75.3 ± 7.1 68.1 ± 11.0 73.9 ± 7.7
Height (m)# 1.72 ± 0.10 1.80 ± 0.05 1.73 ± 0.11 1.78 ± 0.04
BMI (kg m−2) 22.8 ± 2.3 23.1 ± 1.6 22.6 ± 2.3 23.4 ± 1.6
V̇O
2max
 (mL kg−1 min−1) 46.8 ± 10.4 48.4 ± 6.8 48.5 ± 6.3 46.2 ± 11.9
Wmax (W) 269 ± 81 293 ± 33 271 ± 53 287 ± 83
Caffeine intake (mg day−1) 143 ± 139 104 ± 126 121 ± 128 135 ± 145
[Low, moderate, high] [7, 2, 2] [6, 0, 1] [7, 2, 1] [6, 0, 2]
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post-caffeine supplementation, compared with placebo 
(P < 0.01, Fig. 3). At rest pre-supplementation, there were 
no differences in caffeine–placebo PVT change scores 
between ADORA2A or CYP1A2 genotypes (P > 0.05). 
No differences in caffeine–placebo PVT change scores 
emerged between ADORA2A genotypes during exercise or 
at rest post-supplementation (‘high’ vs. ‘low’ sensitivity; 
P > 0.05, Fig. 4). During exercise, caffeine–placebo change 
scores for reaction time were lower in ‘fast’ compared with 
‘slow’ metabolisers (P < 0.01, Cohen’s d = 1.6; Fig. 5a). 
Furthermore, caffeine–placebo change scores for response 
speed and slowest 10% response speed were higher among 
‘fast’ compared with ‘slow’ metabolisers during exercise 
(P < 0.01, Cohen’s d = 1.5 and 1.9, respectively; Fig. 5c, 
d). In addition, caffeine–placebo change scores for the fast-
est 10% reaction time and number of lapses were lower 
for ‘fast’ compared with ‘slow’ metabolisers at rest post-
supplementation (P < 0.05, Cohen’s d = 1.1 and P < 0.01, 
Cohen’s d = 1.7, respectively; Fig. 5b, e). No differences 
in PVT caffeine–placebo change scores emerged between 
Fig. 2  Caffeine–placebo change scores for total work performed dur-
ing 15-min cycling time trial. a, b ADORA2A genotype ‘high’ (filled 
bars) and ‘low’ sensitivity to caffeine (open bars). c, d CYP1A2 gen-
otype ‘fast’ (filled bars) and ‘slow’ caffeine metabolisers (open bars). 
a, c Bars represent individual participants. b, d Data are mean ± SD
Fig. 3  Psychomotor vigilance test reaction time for caffeine (filled 
squares) and placebo trials (open squares) measured at rest pre-sup-
plementation, during exercise, and at rest post-supplementation. Data 
are mean ± SD. **P < 0.01, vs. placebo; †††P < 0.001, vs. pre
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Fig. 4  Psychomotor vigilance test caffeine–placebo change scores 
for a reaction time, b fastest 10% reaction time, c response speed, d 
slowest 10% response speed, and e number of lapses during exercise 
and at rest post-supplementation. Participants are categorised accord-
ing to ADORA2A genotype: ‘high’ (filled bars) or ‘low’ sensitivity to 
caffeine (open bars). Data are mean ± SD
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Fig. 5  Psychomotor vigilance test caffeine–placebo change scores 
for a reaction time, b fastest 10% reaction time, c response speed, d 
slowest 10% response speed, and e number of lapses during exercise 
and at rest post-supplementation. Participants are categorised accord-
ing to CYP1A2 genotype: ‘fast’ (filled bars) or ‘slow’ caffeine metab-
olisers (open bars). Data are mean ± SD. #P < 0.05 and ##P < 0.01, 
between genotypes
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‘high’ sensitivity, ‘fast’ metabolisers compared with all 
others (P > 0.05).
Serum caffeine and paraxanthine
Serum caffeine and paraxanthine concentrations increased 
after caffeine ingestion, and were higher than during the 
placebo trial, 30 and ~ 120  min post-supplementation 
(P < 0.001, Fig. 6a, b). The serum paraxanthine:caffeine 
ratio increased after caffeine consumption, and was 
greater than during the placebo trial after 30 and ~ 120 min 
(P < 0.05, Fig.  6c). No differences in caffeine–placebo 
change scores for serum caffeine, paraxanthine, or the 
paraxanthine:caffeine ratio emerged between genotypes 
(‘high’ vs. ‘low’ sensitivity, ‘fast’ vs. ‘slow’ metabolis-
ers, and ‘high’ sensitivity, ‘fast’ metabolisers vs. ‘others’; 
P > 0.05, Table 2).
Discussion
This randomised, placebo-controlled trial is the first to exam-
ine both the separate and combined influence of two genetic 
polymorphisms (ADORA2A rs5751876 and CYP1A2 
rs762551) on the ergogenic effects of caffeine (3 mg kg−1 
body mass). Aligned with the hypothesis, CYP1A2 genotype 
did affect cognitive performance—with a greater beneficial 
effect of caffeine observed in ‘fast’ metabolisers (Fig. 5). 
In contrast and contrary to the hypothesis, ADORA2A 
genotype did not influence the positive effect of caffeine 
on cognitive performance (Fig. 4). Neither ADORA2A nor 
CYP1A2 genotype affected the ergogenic effect of caffeine 
on endurance exercise performance (Fig. 2). With regards 
to caffeine metabolism, genotype did not affect serum caf-
feine or paraxanthine concentrations 30 and ~ 120-min post-
caffeine consumption (Table 2). The effect of caffeine on 
exercise and cognitive performance and metabolism was not 
different between individuals with ‘high’ sensitivity, ‘fast’ 
metabolism, and all others.
Endurance exercise performance
This is the first study to examine the effect of ADORA2A 
genotype on exercise performance in a cohort of men and 
women. The present results show that ADORA2A genotype 
did not influence performance in a 15-min cycling time trial. 
These novel findings contrast with the only existing study, 
where caffeine (5-mg kg−1 body mass) was ergogenic in a 
10-min time trial for only ‘high’ sensitivity women (Loy 
et al. 2015). In the present study, all but one of the ‘low’ sen-
sitivity participants were homozygous for the C allele. The 
inclusion of several ‘low’ sensitivity women heterozygous 
for the C allele by Loy et al. (2015) may account for these 
divergent findings—it remains unclear whether CT and CC 
individuals respond differently to caffeine. To illustrate, null 
and detrimental effects of caffeine on exercise performance 
have been seen in hetero- and homozygous CYP1A2 ‘slow’ 
metabolisers, respectively (Guest et al. 2018). ADORA2A 
genotype has been found to be associated with habitual caf-
feine intake (Cornelis et al. 2007), which could account for 
Fig. 6  Serum a caffeine, b paraxanthine, and c the 
paraxanthine:caffeine ratio for caffeine and placebo trials measured 
pre-supplementation, and 30-min and ~ 120-min post-supplementa-
tion. Data are mean ± SD. *P < 0.05, **P < 0.01 and ***P < 0.001, vs. 
placebo; ‡‡P < 0.01, vs. 30 min; †P < 0.05 and †††P < 0.001, vs. pre
European Journal of Applied Physiology 
1 3
between-genotype differences in performance following 
acute supplementation (Bell and McLellan 2002). There 
were no between-genotype differences in habitual caffeine 
consumption in the present study—furthermore, in contrast 
to Bell and McLellan’s (2002) methodology, participants in 
the present study were instructed to abstain from caffeine 
for 48 h prior to the experimental trials to help control for 
any effect their habitual intake might have on the ergogenic 
effects of caffeine. This approach also allowed the effect of 
genotype per se to be examined, rather than a phenotypic 
response influenced by habitual intake. Future studies aim-
ing to examine the potential influence of habitual caffeine 
intake on caffeine sensitivity would require larger numbers 
of individuals with low and high caffeine intake. The most 
ecologically valid design for this purpose would also require 
participants to continue with their normal habitual intake in 
the days before the experimental trials.
That CYP1A2 genotype did not affect exercise perfor-
mance is in agreement with the previous studies that have 
assessed performance using a 15-min time trial (Algrain 
et al. 2016) and a shorter duration 3-km time trial (Giersch 
et al. 2018). However, no ergogenic effect of caffeine was 
observed in the 15-min time trial study of Algrain et al. 
(2016) (using caffeinated chewing gum)—probably pre-
cluding an effect of genotype. A caffeine dose > 3-mg kg−1 
body mass may be necessary for genotypic differences to 
be detected, because in all studies where an influence of 
genotype on endurance exercise performance has emerged, 
a 4–6-mg kg−1 body mass dose was used (Guest et al. 2018; 
Loy et al. 2015; Pataky et al. 2016; Womack et al. 2012). 
However, this theory is not supported by Geirsch et al. 
(2018), where CYP1A2 genotype did not influence 3-km 
time trial performance despite 6-mg kg−1 body mass caffeine 
ingestion. It may be caffeine enhances ‘fast’ metabolisers’ 
performance more than ‘slow’ metabolisers only in perfor-
mance tests of a duration greater than 15 min; for example, 
a 10- or 40-km time trial (Guest et al. 2018; Womack et al. 
2012). This proposal is supported by the absence of an effect 
of genotype in the present study, and on Wingate power out-
put (Salinero et al. 2017), a 3-km time trial (Giersch et al. 
2018), and contradictory greater benefit of caffeine in ‘slow’ 
metabolisers in a 3-km time trial (Pataky et al. 2016). The 
relevance of the (i) caffeine dose and (ii) duration of exercise 
performance tests may be related to caffeine metabolism and 
between-genotype variability in the availability of caffeine 
and its metabolites. However, no measurements of caffeine 
metabolites were made in studies where genotype has been 
shown to influence exercise performance (Guest et al. 2018; 
Loy et al. 2015; Pataky et al. 2016; Womack et al. 2012), 
and hence, the role of metabolism per se remains unproven.
Caffeine metabolism
There were no between-genotype differences in caffeine 
metabolism in the present study. In further support of these 
findings, data from our pilot study in healthy men and 
women (n = 16) also found no effect of genotype on caf-
feine metabolism 30 and 120-min post-caffeine ingestion 
(3-mg kg−1 body mass; Online Resource Supplementary 
Fig. 1). Similarly, an earlier study found that caffeine phar-
macokinetics were not different between ‘fast’ and ‘slow’ 
metabolisers up to 65 min after chewing gum containing 
300 mg of caffeine (Algrain et al. 2016). The absence of an 
effect of CYP1A2 genotype on exercise performance in the 
present study is possibly due to the observed lack of any 
pharmacokinetic differences over the study period (i.e., up 
to 120 min after caffeine ingestion). Faster clearance of caf-
feine, as was anticipated to occur in ‘fast’ metabolisers, may 
mean impairments in exercise performance relative to ‘slow’ 
metabolisers are avoided, because a build-up of caffeine 
can block adenosine-induced vasodilatation in the coronary 
arteries, thereby reducing myocardial blood flow during 
Table 2  Caffeine–placebo change scores for serum caffeine, paraxanthine and the paraxanthine:caffeine ratio, 30 and ~ 120-min post-supplemen-
tation
Participants are categorised according to ADORA2A (‘high’ or ‘low’ sensitivity) and CYP1A2 genotypes (‘fast’ or ‘slow’ metaboliser)
Data are mean ± SD. P > 0.05, ‘high’ vs. ‘low’ sensitivity and ‘fast’ vs. ‘slow’ metaboliser
ADORA2A CYP1A2
30 min 120 min 30 min 120 min
‘High’ ‘Low’ ‘High’ ‘Low’ ‘Fast’ ‘Slow’ ‘Fast’ ‘Slow’
Δserum caffeine 
(μg mL−1)
+ 1.65 ± 0.95 + 2.12 ± 0.33 + 1.95 ± 0.26 + 1.79 ± 0.20 + 1.95 ± 0.84 + 1.67 ± 0.80 + 1.97 ± 0.28 + 1.80 ± 0.16
Δserum paraxanthine 
(μg mL−1)




+ 0.17 ± 0.18 − 0.04 ± 0.18 + 0.19 ± 0.05 − 0.05 ± 0.57 + 0.08 ± 0.26 + 0.11 ± 0.14 + 0.01 ± 0.44 + 0.23 ± 0.06
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exercise (Higgins and Babu 2013). There were no between-
genotype differences in heart rate in the present study, sug-
gesting that myocardial blood flow was not impaired. Caf-
feine metabolites paraxanthine and theophylline are potent 
adenosine receptor antagonists, and may themselves be ergo-
genic (Graham 2001). Therefore, faster caffeine metabolism 
and subsequent higher metabolite concentrations may result 
in superior performance. For between-genotype differences 
in exercise performance to emerge, the concentration of caf-
feine metabolites, rather than caffeine alone, may need to be 
affected by genotype. For example, a previous randomised-
controlled trial showed that despite reportedly higher serum 
caffeine concentrations in ‘slow’ metabolisers 1 h post-caf-
feine consumption (in contrast to the present results), no 
differences in paraxanthine, theobromine, theophylline, or 
exercise performance emerged between ‘fast’ and ‘slow’ 
metabolisers (Giersch et al. 2018).
The present study lends support to an absence of an effect 
of CYP1A2 genotype on caffeine metabolism 30- and ~ 120-
min post-caffeine ingestion—the window during which most 
caffeine supplementation exercise studies assess perfor-
mance. In studies that have found a performance difference 
between ‘fast’ and ‘slow’ metabolisers (Guest et al. 2018; 
Pataky et al. 2016; Womack et al. 2012), the absence of 
serum metabolite measures means that there is currently no 
evidence to indicate that differences in caffeine metabolism 
are responsible per se. In all of these studies, performance 
was completed within 120 min of supplementation, so the 
between-genotype differences observed were unlikely to 
have been caused by direct differences in caffeine metabo-
lism. The influence of some other mechanism attributable 
to between-genotype differences remains a possibility. 
What other mechanism may be responsible (for example 
local tissue differences in metabolism) remains to be deter-
mined. Importantly, caffeine concentrations measured up to 
an hour after ingestion may be more reflective of caffeine 
absorption than metabolism (Graham 2001). It is possible 
that metabolic and performance differences will emerge 
between genotypes later post-supplementation. For exam-
ple, metabolic activity (ratio of plasma paraxanthine and 
caffeine) has previously been shown to be higher in ‘fast’ 
compared with ‘slow’ metabolisers 5 h after the ingestion 
of 100 mg of caffeine (Sachse et al. 1999). No between-
genotype differences in serum caffeine or paraxanthine were 
present ~ 2 h post-caffeine consumption in the present study. 
Future studies are required to investigate if any between-
genotype differences in pharmacokinetics emerge over a 
longer time course of several hours (it is also interesting that 
the difference between habitual caffeine users and non-users 
was most apparent at 6-h post-supplementation in the study 
of Bell and McLellan (2002), given that genotype might 
influence habitual intake in some individuals). It follows 
that performance measures commencing later or continu-
ing for longer after caffeine ingestion also warrant further 
investigation.
Cognitive performance
ADORA2A genotype did not affect the positive effect of 
caffeine on cognitive performance. In contrast, caffeine 
enhanced CYP1A2 ‘fast’ metabolisers’ cognitive perfor-
mance more than ‘slow’ metabolisers during exercise and 
at rest. In the only other study to date, no effect of CYP1A2 
genotype on reaction times was observed; however, the 
absence of an ergogenic effect of caffeine likely precluded 
the detection of a caffeine–gene interaction (Salinero et al. 
2017). Large effect sizes for the difference between ‘fast’ and 
‘slow’ metabolisers’ PVT change scores were observed in 
the present study, suggesting that these differences may be 
of practical significance. A possible mechanism to explain 
the effects on cognitive performance in ‘fast’ metabolisers 
could be a greater availability of caffeine metabolites within 
the central nervous system where they are active and bind to 
the adenosine receptor, despite no between-genotype differ-
ences in serum. Indeed, the concentration of ‘free’ caffeine 
and paraxanthine in serum may not reflect the concentration 
bound to adenosine receptors, which may have been greater 
in ‘fast’ metabolisers.
Strengths and limitations
The 18 participants in the present study were sufficient 
to meet the calculated sample size requirement, and the 
proportion of individuals with ‘high’ and ‘low’ sensi-
tivity (61% and 39%, respectively) and ‘fast’ and ‘slow’ 
metabolism genotypes (56% and 44%, respectively) were 
similar to those previously reported (Nehlig 2018). How-
ever, this relatively small sample size meant that only one 
participant was a heterozygous carrier of the ADORA2A 
C allele, and only one participant was homozygous for the 
CYP1A2 C allele. Future studies are required to determine 
the influence of these specific genotypes on the ergogenic 
effects of caffeine. However, the present study’s finding 
that CYP1A2 genotype influences the effect of caffeine 
on cognitive performance has practical relevance to the 
majority of the population, since approximately 90% of 
individuals are CYP1A2 AA or AC carriers (Pickering 
and Kiely 2018). The findings of the present study among 
healthy men and women may not be applicable to ath-
letes due to differences in fitness. A notable strength of 
the present study was cognitive performance was assessed 
during exercise and at rest using a PVT, which is a widely 
used test of sustained attention with excellent reliability 
and validity (Lim and Dinges 2008). The assessment of 
cognitive performance during exercise may be particularly 
European Journal of Applied Physiology 
1 3
relevant for athletes and others who engage in exercise 
and cognitive tasks simultaneously. Further strengths 
of the experimental approach used in the current study 
include the recruitment of both men and women; the use 
of an ecologically valid dose of caffeine and timing prior 
to performance assessments—typically used by athletes 
and others (Maughan et al. 2018; Meeusen et al. 2013); 
and the recording of heart rate during exercise, and the 
analysis of caffeine metabolism to better understand the 
potential mechanisms of action. Future studies are required 
to understand the possible role of other polymorphisms 
in ADORA2A, CYP1A2, and other genes involved in the 
response to or metabolism of caffeine before any person-
alised recommendations for the use of this ergogenic aid 
can be made based on genotype.
Conclusions
The present study is the first to investigate the separate and 
combined influence of two SNPs (ADORA2A rs5751876 
and CYP1A2 rs762551) on the ergogenic effects of caf-
feine. The beneficial effect of caffeine on cognitive perfor-
mance during exercise and at rest was greater in CYP1A2 
‘fast’ metabolisers compared with ‘slow’. In contrast, there 
were no differences in cognitive performance between 
individuals with ADORA2A ‘high’ or ‘low’ sensitivity to 
caffeine. Furthermore, no differences in endurance exer-
cise performance or caffeine metabolism emerged between 
ADORA2A or CYP1A2 genotypes. The influence of caf-
feine on metabolism, and exercise and cognitive perfor-
mance was not different between ‘high’ sensitivity, ‘fast’ 
metabolisers and all other individuals. The present study 
provides evidence that an SNP in the CYP1A2 gene—cen-
tral to caffeine metabolism—has a role in the inter-indi-
vidual variability of cognitive performance enhancement 
observed after caffeine ingestion. It would be of interest 
to examine the influence of other polymorphisms in these 
genes and others involved in caffeine’s ergogenic actions in 
a larger sample that includes more ‘well-trained’ athletes.
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